Diclofenac

Manuscripts

  1. Manvelian G, Daniels S, Gibofsky A. The pharmacokinetic parameters of a single dose of a novel nano-formulated, lower-dose oral study diclofenac. Postgrad Med. 2012;124:117-123.

 

  1. Manvelian G, Daniels S, Gibofsky A. A phase 2 study evaluating the efficacy and safety of a novel, proprietary, nano-formulated, lower-dose oral diclofenac. Pain Med. 2012;13:1491-1498.

 

  1. Gibofsky A, Silberstein S, Argoff C, Daniels S, Jensen S, Young CL. Lower-dose diclofenac submicron particle capsules provide early and sustained acute patient pain relief in a phase 3 study. Postgrad Med. 2013;125:130-138.

 

  1. Manvelian G, Daniels S, Gibofsky A. Erratum to: A phase 2 study evaluating the efficacy and safety of a novel, proprietary, nano-formulated, lower-dose oral diclofenac. Pain Med. 2013;14:1615.

 

  1. Odom DM, Mladsi DM, Saag KG, et al. Relationship between diclofenac dose and risk of gastrointestinal and cardiovascular events: meta-regression based on two systematic literature reviews. Clin Ther. 2014;36(6):906-917.

 

  1. Gibofsky A, Hochberg MC, Jaros MJ, Young CL. Efficacy and safety of low-dose submicron diclofenac for the treatment of osteoarthritis pain: a 12 week, phase 3 study. Curr Res Med Opin. 2014;30:1883-1893.

 

  1. Desjardins PJ, Olugemo K, Solorio D, Young CL. Pharmacokinetic properties and tolerability of low-dose SoluMatrix diclofenac. Clin Ther. 2015;37(2):448-461.

 

  1. Altman RD, Strand V, Hochberg MC, et al. Low-dose SoluMatrix diclofenac in the treatment of osteoarthritis: a 1-year, open-label, phase III safety study. Postgrad Med. 2015;127(5):517-528.

 

  1. Altman R, Bosch B, Brune K, Patrignani P, Young C. Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology. Drugs. 2015;75(8):859-877.

 

  1. Gibofsky A, Altman R, Daniels S, Imasogie O, Young C. Low-dose SoluMatrix diclofenac: a review of safety across two phase III studies in patients with acute and osteoarthritis pain. Expert Opin Drug Saf. 2015;14(8):1327-1339.

 

  1. Argoff C, McCarberg B, Gudin J, Nalamachu S, Young C. SoluMatrix diclofenac: sustained opioid-sparing effects in a phase 3 study in patients with postoperative pain. Pain Med. 2016. Mar 19. pii: pnw012.

 

  1. Mladsi D, Ronquest N, Odom D, Miles L, Saag K. Cost-effectiveness of low-dose submicron diclofenac compared with generic diclofenac. Clin Ther. 2016 Nov;38(11):2418-2429.

 

Abstracts

  1. Daniels S, Manvelian G, Gibofsky A. A phase 2 study evaluating the efficacy and safety of a novel, proprietary, nano-formulated oral diclofenac. Presented at: 2011 World Congress on Osteoarthritis. September 15-18, 2011; San Francisco, CA. Published in: Osteoarthr Cartil. 2011;19(Suppl 1):S144-S145.

 

  1. Gibofsky A, Daniels S, Manvelian G. Acute pain relief by a proprietary, nano-formulated lower-dose oral diclofenac. Presented at: 2012 Annual Meeting of the American Academy of Pain Medicine. February 23-26, 2012; Palm Springs, CA. Program and abstracts of the 2012 Annual Meeting American Academy of Pain Medicine; Abstract 228.

 

  1. Manvelian G, Daniels S, Gibofsky A. The pharmacokinetic parameters of a novel, nano-formulated lower-dose oral diclofenac. Presented at: 2012 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. March 12-17, 2012; National Harbor, MD. Published in: Clin Pharmacol Ther. 2012;91:S55.

 

  1. Gibofsky A, Daniels S, Manvelian G. Acute pain relief by a proprietary, nano-formulated lower-dose oral diclofenac. Presented at: 2012 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. March 12-17, 2012; National Harbor, MD. Published in: Clin Pharmacol Ther. 2012;91:S55.

 

  1. Manvelian G, McCarberg B. Acute pain relief by a proprietary, nano-formulated lower-dose oral diclofenac. Presented at: 31st Annual Meeting of the American Pain Society. May 16-19, 2012; Honolulu, HI. Published in: J Pain. 2012;13(Suppl):S74.

 

  1. Odom D, Mladsi D, Saag K, Ang D, Ronquest N, Wang J. Estimating the relationship between diclofenac drug dosage and risk of gastrointestinal toxicity: meta-regression based on a systematic literature review. Presented at: Digestive Disease Week. May 19-22, 2012; San Diego, CA. Published in: Gastroenterology. 2013;144(5):S673.

 

  1. Kuss M, Manvelian G. Acute pain relief by a nano-formulated, lower-dose, oral diclofenac. Presented at: 14th World Congress on Pain. August 27-31, 2012; Milan, Italy. Program and abstracts of the 14th World Congress on Pain; Abstract 385.

 

  1. Silberstein S, Argoff C, Gibofsky A, Daniels S, Jensen S, Young C. Results from the pivotal phase 3 trial of nano-formulated, lower-dose diclofenac demonstrating early and sustained acute pain relief. Presented at: 54th Annual Scientific Meeting of the American Headache Society. June 15-18, 2012; Scottsdale, AZ. Published in: Headache. 2012;52(6):1055.

 

  1. Argoff C, Silberstein S, Gibofsky A, Daniels S, Jensen S, Young C. Diclofenac submicron particle capsules demonstrate early and sustained acute pain relief. Presented at: 23rd Annual Clinical Meeting of the American Academy of Pain Management. September 20-23, 2012; Phoenix, AZ. Program and abstracts of the 23rd Annual Clinical Meeting of the American Academy of Pain Management; Abstract 25.

 

  1. Argoff C, Silberstein S, Gibofsky A, Daniels S, Jensen S, Young C. Diclofenac submicron particle capsules demonstrate early and sustained acute pain relief. Presented at: 2013 Annual American Academy of Pain Medicine Meeting. April 10-14, 2013; Ft. Lauderdale, FL. Program and abstracts of the 2013 American Academy of Pain Medicine Meeting; Abstract 138.

 

  1. Argoff C, Silberstein S, Gibofsky A, Daniels S, Jensen S, Young C. Diclofenac submicron particle capsules demonstrate early and sustained acute pain relief in a phase 3 study in patients following bunionectomy surgery. Presented at: World Congress on Osteoarthritis. April 18-21, 2013; Philadelphia, PA. Published in: Osteoarthr Cartil. 2013;21(Suppl):S291.

 

  1. Gibofsky A, Hochberg M, Young C. A phase 3 study of lower-dose diclofenac submicron particle capsules demonstrates effective pain relief in patients with osteoarthritis. Presented at: World Congress on Osteoarthritis. April 18-21, 2013; Philadelphia, PA. Published in: Osteoarthr Cartil. 2013;21(Suppl):S267.

 

  1. Jensen S, Argoff C, Daniels S, Young C. Diclofenac submicron particle capsules demonstrate analgesia in a phase 3 study of patients with acute pain. Presented at: 28th National Conference of the American Association of Nurse Practictioners. June 19-23, 2013; Las Vegas, NV.

 

  1. Argoff C, Nalamachu S, Webster L, Young C. Diclofenac submicron particle capsules reduce opioid rescue medication use in a phase 3 study in patients with acute pain following elective surgery. Presented at: PAINWeek 2013. September 4-7, 2013; Las Vegas, NV. Program and abstracts of PAINWeek 2013; Abstract 139.

 

  1. Mladsi D, Ronquest N, Tannus G, Fonseca M, Saag KG. Estimated cost effectiveness of lower-dose submicron diclofenac compared with traditional diclofenac in Brazil. Presented at: ISPOR 4th Latin America Conference. September 12-14, 2013; Buenos Aires, Argentina. Published in: Value Health. 2013;16(7):A717-A718.

 

  1. Kuss M, Nezzer J, Young C. A phase 3 study of lower-dose diclofenac submicron particle capsules demonstrates effective pain relief in patients with osteoarthritis. Presented at: 8th Congress of the European Federation of IASP Chapters (EFIC). October 9-12, 2013; Florence, Italy. Program and abstracts of the 8th Congress of the EFIC; Abstract 666.

 

  1. Young C, Hochberg M. Safety of lower-dose diclofenac submicron particle capsules dosed to 12 weeks in patients with osteoarthritis. Presented at: American College of Rheumatology Annual Meeting. October 26-30, 2013; San Diego, CA. Published in: Arthritis Rheum. 2013;65(Suppl 10):S882.

 

  1. Argoff C, Parenti D, Young C. Lower-dose diclofenac submicron particle containing capsules: review of pharmacokinetic properties, efficacy, and tolerability. Poster presented at: Eastern Pain Association Annual Meeting. December 7, 2013; New York, NY.

 

  1. Argoff C, Nalamachu S, Webster L, Young C. Diclofenac submicron particle capsules reduce opioid rescue medication usage in a phase 3 study in patients with acute pain following elective surgery. Presented at: 30th Annual American Academy of Pain Medicine Meeting. March 6-9, 2014; Phoenix, AZ. Program and abstracts of the 30th Annual American Academy of Pain Medicine; Abstract 197.

 

  1. Solorio D, Gan T, Webster L, Gibofsky A, Young C. Lower dose diclofenac capsules provide clinically meaningful reductions in pain in a phase 3 study of patients following bunionectomy. Presented at: American Society of Regional Anesthesia and Pain Medicine Spring Meeting. April 3-6, 2014; Chicago, IL. Program and abstracts of the 2014 American Society of Regional Anesthesia and Pain Medicine Spring Meeting; Abstract EP05.

 

  1. Young C, Parenti D, Hochberg M. Lower-dose diclofenac capsules developed using SoluMatrix Fine Particle Technology result in clinically meaningful improvements in pain in a phase 3 study of patients with osteoarthritis. Presented at: 2014 World Congress on Osteoarthritis. April 24-27, 2014; Paris, France. Published in: Osteoarthr Cartil. 2014;22(Suppl):S399.

 

  1. Strand V, Bergman M, Parenti D, Nezzer J, Young C. A phase 3 randomized controlled trial of lower-dose diclofenac capsules developed using SoluMatrix Fine Particle Technology in patients with osteoarthritis pain: impact on patient-reported outcomes. Presented at: 2014 World Congress on Osteoarthritis. April 24-27, 2014; Paris, France. Published in: Osteoarthr Cartil. 2014;22(Suppl):S392-S393.

 

  1. Daniels S, Solorio D, Young C. Lower-dose diclofenac capsules using SoluMatrix Fine Particle Technology provide effective pain relief in a phase 3 study of patients with acute pain following bunionectomy. Presented at: 33rd Annual Scientific Meeting of the American Pain Society. April 30-May 3, 2014; Tampa, FL. Published in: J Pain. 2014;15(Suppl):S77.

 

  1. Argoff C, Nalamachu S, Webster L, Gudin J, Young C. SoluMatrix diclofenac demonstrates opioid-sparing effects in a phase 3 study of patients with acute pain following elective surgery. Presented at: PAINWeek. September 2-6, 2014; Las Vegas, NV. Published in: Postgrad Med. 2014;126(Suppl):S105-S106.

 

  1. Strand V, Gibofsky A, Hochberg M, et al. A phase 3 open-label trial of low-dose SoluMatrix diclofenac in patients with osteoarthritis pain: impact of long-term administration on patient-reported outcomes. Presented at: 2014 ACR/ARHP Annual Meeting. November 15-19, 2014; Boston, MA. Published in: Arthritis Rheumatol. 2014;66(Suppl 11):S104.

 

  1. Altman R, Hochberg M, Gibofsky A, et al. Safety of SoluMatrix diclofenac in adults with osteoarthritis: results of a 12-month, phase 3 study. Presented at: 2014 ACR/ARHP Annual Meeting. November 15-19, 2014; Boston, MA. Published in: Arthritis Rheumatol. 2014;66(Suppl 11):S101-S102.

 

  1. Altman RD, Hochberg M, Gibofsky A, Tenzer P, Young CL. SoluMatrix diclofenac safety in older patients with osteoarthritis pain. Presented at: 2015 World Congress on Osteoarthritis (OARSI). April 30-May 3, 2015; Seattle, WA. Published in: Osteoarthr Cartil. 2015;23(Suppl 2):A335-A336.

 

  1. Mladsi DM, Goyal RK, Cryer B, et al. Risk of cardiovascular, gastrointestinal, and renal adverse events associated with diclofenac immediate and extended release drug products: an observational study using US claims data. Presented at: ISPOR 20th Annual International Meeting. May 16-20, 2015; Philadelphia, PA. Published in: Value Health. 2015;18(3):A292.

Indomethacin

Manuscripts

  1. Manvelian G, Daniels S, Altman R. A phase I study evaluating the pharmacokinetic profile of a novel, proprietary, nano-formulated, lower-dose oral indomethacin. Postgrad Med. 2012;124:197-205.

 

  1. Altman R, Daniels S, Young CL. Indomethacin submicron particle capsules provide effective pain relief in patients with acute pain: a phase 3 study. Phys Sportsmed. 2013;41:7-15.

 

  1. Manvelian G, Hochberg MC, Daniels SE, Altman RD, Young CL. A phase 2 study of lower-dose indomethacin submicron particle capsules demonstrates early onset of acute pain relief. Clin J Pain. 2013;30(10):846-851.

 

  1. Olugemo K, Solorio D, Sheridan C, Young CL. Pharmacokinetics and safety of low-dose submicron indomethacin 20 and 40 mg compared with indomethacin 50 mg. Postgrad Med. 2015;127(2):223-231.

 

Abstracts

  1. Manvelian G, Derendorf H. The pharmacokinetic parameters of a novel, nano-formulated oral indomethacin. Presented at: 53rd Annual Scientific Meeting of the American Headache Society. June 2-5, 2011; Washington, DC. Published in: Headache. 2011;51:58-59.

 

  1. Manvelian G, Daniels S. A phase 2 study evaluating the efficacy and safety of a novel, proprietary, nano-formulated oral indomethacin. Presented at: 2011 World Congress on Osteoarthritis. September 15-18, 2011; San Diego, CA. Published in: Osteoarthr Cartil. 2011;19(Suppl 1):S145.

 

  1. Altman R, Daniels S, Manvelian G. Acute pain relief by a proprietary, nano-formulated lower-dose oral indomethacin. Presented at: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting. November 4-9, 2011; Chicago, IL. Published in: Arthritis Rheum. 2011;63(Suppl 10):1280.

 

  1. Altman R, Daniels S, Young C. Lower-dose indomethacin submicron particle capsules demonstrate effective analgesia in a phase 3 post-surgical moderate to severe pain model study. Presented at: 29th Meeting of the American Academy of Pain Medicine. April 10-14, 2013; Ft. Lauderdale, FL. Programs and abstracts of the American Academy of Pain Medicine; Abstract 109.

 

  1. Altman R, Saag K, Daniels S, Young C. Lower-dose indomethacin submicron particle capsules provide effective acute pain relief: phase 3 study results. Presented at: 2013 World Congress on Osteoarthritis. April 18-21, 2013; Philadelphia, PA. Published in: Osteoarthr. 2013;21(Suppl):S267-S268.

 

  1. Altman R, Saag K, Daniels S, Young C. Efficacy of lower-dose indomethacin submicron particle capsules in a phase 3 study of patients with acute pain. Presented at: 28th National Conference of the American Association of Nurse Practitioners. June 20-22, 2013; Las Vegas, NV.

 

  1. Altman R, Saag K, Daniels S, Solorio D, Young C. Lower-dose indomethacin submicron particle capsules provide effective acute pain relief: phase 3 study results. Presented at: 24th Annual Clinical Meeting of the American Academy of Pain Management. September 26-29, 2013; Orlando, FL. Program and abstracts of the 24th Annual Clinical Meeting of the American Academy of Pain Management; Abstract 17.

 

  1. Altman R, Gibofsky A, Jaros M, Young C. Lower-dose indomethacin submicron particle capsules’ efficacy in acute pain: results from two phase 3 studies. Presented at: American College of Rheumatology 2013 Annual Meeting. October 25-30, 2013; San Diego, CA. Published in: Arthritis Rheum. 2013;65(Suppl 10):S872-S873.

 

  1. Gibofsky A, Altman R, Young C, Solorio D, Nezzer J. Lower-dose indomethacin submicron particle capsules’ combined safety from two phase 3 studies in patients with acute pain following elective surgery. Presented at: American College of Rheumatology 2013 Annual Meeting. October 25-30, 2013; San Diego, CA. Published in: Arthritis Rheum. 2013;65(Suppl 10):S873.

 

  1. Altman R, Jaros M, Young C. Lower-dose indomethacin submicron particle capsule efficacy in acute pain: results from two phase 3 studies. Presented at: 30th Annual American Academy of Pain Medicine Meeting. March 6-9, 2014; Phoenix, AZ. Program and abstracts of the 30th Annual American Academy of Pain Medicine Meeting; Abstract 196.

 

  1. Olugemo K, Solorio D, Sheridan C, Young C. Pharmacokinetics of lower-dose indomethacin submicron particle capsules 20 and 40 mg compared with indomethacin 50 mg capsules in healthy volunteers. Presented at: American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2014 Annual Meeting. March 18-22, 2014; Atlanta, GA. Published in: Clin Pharmacol Ther. 2014;95(Suppl):S88.

 

  1. Webster L, Altman R, Nalamachu S, Markenson J, Solorio D, Young C. Lower dose SoluMatrix indomethacin capsules developed using SoluMatrix Fine Particle Technology: relationship of pharmacokinetic properties and onset of analgesia. Presented at: American Society of Regional Anesthesia and Pain Medicine Spring Meeting. April 3-6, 2014; Chicago, IL. Program and abstracts of the 2014 American Society of Regional Anesthesia and Pain Medicine Spring Meeting; Abstract EP05

 

  1. Jaros M, Nezzer J, Solorio D, Young C. Sensitivity analyses show additional efficacy of indomethacin submicron particle capsules in a phase 3 study in patients experiencing acute pain following elective surgery. Presented at: 33rd Annual Scientific Meeting of the American Pain Society. April 30-May 3, 2014; Tampa, FL. Published in: J Pain. 2014;15(Suppl):S76.

 

  1. Gibofsky A, Babar N, Altman R, Solorio D, Young C. Indomethacin submicron particle capsules: reduced opioid rescue medication usage in a phase 3 study in patients with acute pain after elective surgery. Presented at: 33rd Annual Scientific Meeting of the American Pain Society. April 30-May 3, 2014; Tampa, FL. Published in: J Pain. 2014;15(Suppl):S76.

 

  1. Altman R, Gibofsky A, Parenti D, Young C. Lower-dose SoluMatrix indomethacin efficacy in acute pain: results from two phase 3 studies. Presented at: the European League Against Rheumatism annual meeting. June 11-14, 2014; Paris, France. Published in: Ann Rheum Dis. 2014;73(Suppl 2):298.

 

  1. Altman R, Gibofsky A, Parenti D, Young C. Lower-dose SoluMatrix indomethacin: combined safety data from two phase 3 studies in patients with acute pain following elective surgery. Presented at: the European League Against Rheumatism annual meeting. June 11-14, 2014; Paris, France. Published in: Ann Rheum Dis. 2014;73(Suppl 2):298-299.

 

  1. Gibofsky A, Altman R, Gharibo C, Babar NS, Solorio D, Young C. Low-dose SoluMatrix indomethacin: reduced opioid rescue medication use in a phase 3 study in patients with acute pain following bunionectomy. Presented at: PainWeek. September 2-6, 2014; Las Vegas, NV. Published in: Postgrad Med. 2014;126(Suppl):S105-S106.

 

Reviews

  1. Nalamachu S, Wortmann R. Role of indomethacin in acute pain and inflammation management: a review of the literature. Postgrad Med. 2014;126:92-97.

Meloxicam

Manuscripts

  1. Altman R, Hochberg M, Gibofsky A, Jaros M, Young C. Efficacy and safety of low-dose SoluMatrix meloxicam in the treatment of osteoarthritis pain: a 12-week, phase 3 study. Curr Med Res and Opin. 2015;31(12):2331-2343.

 

  1. Hussaini A, Solorio D, Young C. Pharmacokinetic properties of low-dose SoluMatrix meloxicam in healthy adults. Clin Rheumatol. 2016;35(4):1099-1104.

 

Abstracts

  1. Olugemo K, Parenti D, Young C. Pharmacokinetics and safety of lower-dose SoluMatrix meloxicam in healthy adults. Published in: Ann Rheum Dis. 2014;73(Suppl 2):1089. (Not Presented at: the European League Against Rheumatism annual meeting. June 11-14, 2014; Paris, France.)

 

  1. Altman R, Hochberg M, Gibofsky A, Parenti D, Young C. Lower-dose SoluMatrix meloxicam: efficacy and safety in a phase 3 study in adults with osteoarthritis pain. Presented at: the European League Against Rheumatism annual meeting. June 11-14, 2014; Paris, France. Published in: Ann Rheum Dis. 2014;73(Suppl 2):250-251.

 

  1. Altman R, Hochberg M, Gibofsky A, Kwong L, Young C. Low-dose SoluMatrix meloxicam demonstrates low systemic exposure and efficacy in patients with osteoarthritis pain in clinical studies. Presented at: 2015 World Congress on Osteoarthritis (OARSI). April 30-May 3, 2015; Seattle, WA. Published in: Osteoarthr Cartil. 2015;23(Suppl 2):A324-A325.

 

  1. Altman R, Cryer B, Gibofsky A, et al. Safety of low-dose SoluMatrix meloxicam in adults with osteoarthritis: results of a 12-month, phase 3 safety study. Presented at: 2015 PainWeek. September 8-12, 2015; Las Vegas, NV. Published in: Postgrad Med. 2015;127:S105-S106.

 

  1. Altman R, Hochberg M, Kivitz A, et al. SoluMatrix meloxicam safety in older patients with osteoarthritis. Presented at: 2016 World Congress on Osteoarthritis (OARSI). March 31-April 3, 2016; Amsterdam, Netherlands. Published in: Osteoarthr Cartil. 2016;24:S188.

 

  1. Altman R, Hochberg M, Kivitz A, Gibofsky A, Solorio D, Young C. Low-dose SoluMatrix meloxicam results in clinically meaningful improvements in pain in a phase 3 study of patients with osteoarthritis. Presented at: 2016 World Congress on Osteoarthritis (OARSI). March 31-April 3, 2016; Amsterdam, Netherlands. Published in: Osteoarthr Cartil. 2016;24:S419.

 

  1. Altman R, Gibofsky A, Kivitz A, Solorio D, Sheridan C, Young C. A novel application of the Medication Event Monitoring System (MEMS) to track rescue medication use in a phase 3 study of low-dose SoluMatrix meloxicam in patients with osteoarthritis (OA) pain. Presented at: 2016 American Pain Society 35th Annual Scientific Meeting. May 11-14, 2016; Austin, TX. Published in: J Pain. 2016;17(4)(Suppl):S70.

 

  1. Young C, Solorio D, Sheridan C, Imasogie O, O’Brien D, Vrijens B. Novel use of a medication event monitoring system to track rescue use in a trial of a new meloxicam drug product. Presented at: Drug Information Association (DIA) 2016 Annual Meeting. June 26-30, 2016; Philadelphia, PA.

 

Naproxen

Manuscripts

  1. Young CL, Strand V, Altman R, Daniels S. A phase 2 study of naproxen submicron particle capsules in patients with post-surgical dental pain. Adv Ther. 2013;30(10):885-896.

 

Abstracts

  1. Manvelian G, Daniels S, Gibofsky A, Strand V. A phase 2 study evaluating the acute pain relief of a nano-formulated oral naproxen. Presented at: 2011 Annual Meeting American College of Rheumatology. November 4-11, 2011; Chicago, IL. Published in: Arthritis Rheum. 2011;63(Suppl 10):1281.

 

  1. Altman R, Daniels S, Manvelian G. A proprietary, nano-formulated, lower dose oral naproxen provides effective pain relief. Presented at: 2012 World Congress on Osteoarthritis. April 26-29, 2012; Barcelona, Spain. Published in: Osteoarthr Cartil. 2012;20(Suppl 1):S285-S286.

 

  1. Manvelian G, McCarberg B. Nano-formulated lower dose oral naproxen provides faster acute pain relief than traditional naproxen. Presented at: 31st Annual Meeting of the American Pain Society. May 16-19, 2012; Honolulu, HI. Published in: J Pain. 2012;13(Suppl):S75.

Franchise

Abstracts

  1. Manvelian G, Altman R, Strand V. Application of nanotechnology to improve non-steroidal anti-inflammatory drugs. Presented at: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting. November 4-9, 2011; Chicago, IL. Published in: Arthritis Rheum. 2011;63(Suppl 10):1282.

 

  1. Strand V, Altman R, Daniels S, Manvelian G. Safety and efficacy profile of nano-formulated, lower dose non-steroidal anti-inflammatory drugs. Presented at: 2012 World Congress on Osteoarthritis. April 26-29, 2012; Barcelona, Spain. Published in: Osteoarthritis Cartilage. 2012;20(Suppl 1):S284-S285.

 

  1. Strand V, Altman R, Daniels S, Manvelian G. Nano-formulated lower dose NSAIDs preferred by patients experiencing acute pain. Ann Rheum Dis. 2012;71(Suppl 3):672.

 

  1. Silberstein S, Daniels S, Gibofsky A, Manvelian G. Efficacy and safety of nano-formulated, lower dose NSAIDs. 54th Annual Scientific Meeting of the American Headache Society. June 21-24, 2012; Los Angeles, CA.

 

  1. Manvelian G, Daniels S, McCarberg B. The effect of lower dose, submicron particle NSAIDs on peak pain relief in patients with acute pain. Presented at: PAINWeek 2012 National Conference.September 5-8, 2012; Las Vegas, NV. [Abstract 55].

 

  1. Copley-Merriman K, Olanrewaju B, Hogue S. Systematic literature review of the temporal relationship between NSAID use and gastrointestinal, cardiovascular, or renal events. Presented at: ISPOR 18th Annual International Meeting. May 18-22, 2013; New Orleans, LA. [Abstract PSY1]. In: Value Health. 2013;16:A110.

 

  1. McCarberg B, Snodgrass B, Craw J, et al. Gaps in consumer awareness of NSAID risks: results of a nationwide survey. Presented at the American Association of Nurse Practitioners 2016 National Conference. June 21-26, 2016; San Antonio, TX.

 

  1. Altman R, Gibofsky A, Snodgrass B, Sheridan C, Solorio D, Young C. SoluMatrix NSAIDs: effective low-dose treatment options for acute and osteoarthritis pain. Presented at the American Association of Nurse Practitioners 2016 National Conference. June 21-26, 2016; San Antonio, TX.

 

Reviews

  1. McCarberg B, Gibofsky A. Need to develop new nonsteroidal anti-inflammatory drug formulations. Clin Ther. 2012;34(9):1954-1963.

 

  1. McCarberg B, Tenzer P. Complexities in the pharmacologic management of osteoarthritis pain. Curr Med Res Opin. 2013;29(5):539-548.

 

  1. McCarberg BH, Cryer B. Evolving therapeutic strategies to improve nonsteroidal anti-inflammatory drug safety. Am J Ther. 2015;22(6):e167-e178.

Other Iroko Supported Publications

  1. Nalamachu S, Pergolizzi JV, Raffa RB, Lakkireddy DR, Taylor R Jr. Drug-drug interaction between NSAIDs and low-dose aspirin: a focus on cardiovascular and GI toxicity. Expert Opin Drug Saf. 2014;13(7):903-917.

 

  1. Goldstein JL, Cryer B. Gastrointestional injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf. 2015;7:31-41.

 

  1. Pollack CV Jr, Viscusi ER. Improving acute pain management in emergency medicine. Hosp Pract. 1995;43(1):36-45.

 

  1. Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res. 2015;8:105-118.

 

  1. Lipman A, Webster L. The economic impact of opioid use in the management of chronic nonmalignant pain. J Manag Care Pharm. 2015;21(10):891-899.